Methyllycaconitine citrate is a α7 neuronal nicotinic acetylcholine receptor (α7nAChR)antagonist.

Pretreatment with 5 and 10 μM Methyllycaconitine citrate (MLA) inhibits the decreased cell viability induced by Aβ25-35. [1].

Methyllycaconitine citrate (MLA) (6 mg/kg) given alone intraperitoneally does not cause climbing behavior when compare with the saline group. Pretreatment with Methyllycaconitine citrate significantly inhibits methamphetamine (METH)-induced climbing behavior, by about 50%[1].

351344-10-0

C43H58N2O17

874.92

甲基牛扁亭柠檬酸盐;MLA;Methyllycaconitine citrate

DMSO:250 mg/mL (285.74 mM),Need ultrasonic and warming
H2O:2.18 mg/mL (2.49 mM),Need ultrasonic and warming
Powder: -20°C for 3 years
In solvent: -80°C for 2 years